DEXCOM INC

Dexcom’s 5,841‑share RSU grant signals strong leadership alignment and modest future dilution, giving investors confidence in long‑term value.

Dexcom insiders’ steady, near‑market sales show routine portfolio rebalancing, not a warning—stock remains driven by strong fundamentals and growth.

Kevin R. Sayer’s latest 10b‑5‑1 sale at Dexcom shows routine portfolio management—over 900k shares sold yet the company’s solid growth, cash, and product pipeline stay intact for investors.

Insider sales at Dexcom signal opportunistic divestments, not a loss of confidence—investors should focus on the company’s strong fundamentals and growth pipeline.

Dexcom insiders trim shares as the G7 sensor drives 10‑week gains—yet the board keeps a bullish long‑term stake, signaling confidence in the company’s growth.

Dexcom insider sales by Mark G. Foletta show a routine liquidity move, not a warning—strong fundamentals and bullish sentiment remain intact.

Insider sales: EVP Michael Brown’s July 15th Dexcom share sale shows disciplined 10‑b5‑1 trading, not distress, but signals investors to watch market sentiment and portfolio shifts.

Dexcom insider sale: EVP Brown sells 1,700 shares at $75.55—routine transaction, no short‑term impact, focus on product pipeline & growth.

Insider selling at Dexcom: EVP Michael Jon Brown’s May 2026 sale signals caution amid a 52‑week high, market volatility, and upcoming Dexcom Flex launch.

Dexcom insider Collins Richard Alexander sold and rebought 5,074 shares under a trust, keeping 40,162 shares to safeguard assets while staying committed to the company’s long‑term growth.